

# Lion's Mane

## The Anti-Dementia Effect of Lion's Mane Mushroom (*Hericium erinaceum*) and Its Clinical Application

by Hirokazu Kawagishi, Department of Applied Biological Chemistry, Faculty of Agriculture, Shizuoka University, Japan; Cun Zhuang, BioResearch Institute, Paramus, New Jersey; and Ellen Shnidman, Maitake Products, Inc. Ridgefield Park, New Jersey

### Introduction

Medicinal Mushrooms have become a hot item in the mass media in the last few years but the information being disseminated about them is not always scientifically accurate. Most of the studies on the efficacy of medicinal mushrooms that are available to the public are based on animal studies (usually in mice) or cultured cells. In these cases, the bioactivity of the mushroom extracts cannot always be correlated to their activity when ingested by humans – either orally or by injection.

Our research on components of Lion's Mane mushroom (*Hericium erinaceum*) and their biological activities in cell culture is a case where positive anti-

dementia results in the laboratory have been confirmed by analogous results in human use. In this article, we will introduce both the results from the laboratory and their clinical application.

### Conventional Treatments of Alzheimer's Disease

Alzheimer's disease is primarily a disorder of aging in which individuals become agitated and uncomprehending, with profound loss of cognitive function, ultimately requiring institutionalization. About 1 in 10 people over the age of 65 and as many as 5 out of 10 people over the age of 85 are affected. This disease is characterized biologically by the death of neurons in the forebrain, hippocampus, and cerebral cortex.

The most conventional approach to treatment of Alzheimer's disease currently in practice is to treat the symptoms caused by the death of cholinergic neurons. Four pharmaceutical products approved by the FDA that are presently on the market work by potentiating neurotransmission at cholinergic synapses. These drugs are: Aricept® by Pfizer, Exelon® by Novartis, Reminyl® by Janssen, and Cognex® by First Horizon. None of these products, however, reverses the damage done to cognitive functioning. They simply delay further deterioration. Recently, a new drug called memantine, produced by Forest Laboratories, was approved for use by the FDA. Memantine works by blocking the receptor for the glutamate


neurotransmitter whose overactivity may be responsible for the neurotoxicity of Alzheimer's disease. Likewise, its beneficial effect is only temporary.

### Inducers of Nerve Growth Factor Synthesis *in vitro*

One of the major new approaches to the study of treatments for Alzheimer's disease concerns the search for agents that stimulate Nerve Growth Factor (NGF) production in the brain. NGF is part of a family of proteins that play a role in the maintenance, survival and regeneration of neurons during adult life. Its absence in the adult brain of mice leads to a condition resembling Alzheimer's disease.

Nerve Growth Factor itself cannot be used as an orally administered drug to regenerate brain tissue because it does not cross the blood-brain barrier. If bioactive substances with low molecular weight can be found that penetrate the barrier and induce the synthesis of NGF inside the brain, such substances may be applied as oral agents to prevent this disease. Even if these substances cannot go through the barrier, the enhancement of NGF production would be beneficial for disorders of the peripheral nervous system since NGF has a similar effect on neurons in the periphery.

We have been engaged in a study to search for NGF synthesis-promoting agents in medicinal mushrooms since 1991. We discovered a class of benzyl alcohol and chroman derivatives in the fruit body of Lion's Mane mushroom called the hericenones C-H that stimulate NGF production from mouse astroglial cells in culture.<sup>1-18</sup> Subsequently, we discovered another group of cyathane derivative compounds from the mycelium of the same mushroom called the erinacines A-I that also induce NGF production.<sup>4-22</sup> (Figure 1)



**Figure 1 – Structures of Hericenones and Erinacines from Lion's Mane Mushroom**

### Hericenones Isolated from the Fruit Body of Lion's Mane

The hericenones were derived from Lion's Mane as follows. The fruit body of the mushroom was crushed in acetone by a blender and left for 1-2 days to allow extraction of nonpolar substances. The liquid extract was processed with vacuum filtration and the mushroom fruit body was further extracted twice by acetone. The extract was concentrated using an evaporator until 2 liters of volume was obtained, and then this was fractionated with chloroform. Ethyl acetate was added to the aqueous phase for an additional extraction.

The fractionation of the extract is an essential step for applying the compounds to the NGF assay, because there is an optimum concentration for the activation of NGF synthesis, and also most of the fractions at this stage exhibit cytotoxic activity. For separation purposes, silica gel chromatography and preparative thin layer chromatography (TLC) were employed, and two types of fractions were obtained: one with hericenones C-E and the other with hericenones F-H. Both fractions were spotted at almost the same distance on the silica gel TLC and thus separation was only possible by high performance liquid chromatography (HPLC), using an ODS column.

These compounds were the first active substances found in natural products that are as effective as epinephrine in inducing NGF synthesis *in vitro*. Each group of hericenones, C-E and F-H, contains a characteristic alcohol site, and each hericenone contains one of three simple fatty acids. Hericenone D demonstrated the strongest stimulating activity in synthesis of NGF from astroglial cells. The activity level of these compounds varies according to the structure of its fatty acid constituent.

### Erinacines Isolated from the Mycelium of Lion's Mane

The erinacines were obtained from Lion's Mane as follows. Following 4 weeks in culture, the mycelium was extracted with 85% ethanol. The ethanol extract was concentrated, and then fractionated with ethyl acetate and water. Erinacines A-I were isolated by silica gel column chromatography on HPLC and preparative TLC.

Erinacines A-I are a series of diterpenoids, with different chemical structures from those of the hericenones, that have powerful activities in stimulating NGF synthesis. The activities of erinacines A-G *in vitro* are

shown in Figure 2. As can be seen, all of these compounds are more potent inducers of NGF synthesis than epinephrine. The newly-discovered erinacine H stimulated 31.5 +/- 1.7 pg/ml of NGF secretion into the medium at 33.3 µg/ml concentration, which was five times greater than NGF secretion in the absence of the compound. The erinacines are the most powerful inducers of NGF synthesis among all currently identified natural compounds.

### Clinical Study of Lion's Mane Mushroom on Dementia Patients

Lion's Mane mushroom, therefore, contains at least two types of compounds – the hericenones and erinacines – that strongly stimulate NGF synthesis *in vitro*. Both of these types of substances, potentially, can cross the blood-brain barrier. The question is, do these substances work when given orally to human patients?

To answer this question, a study was done in a rehabilitative hospital in the Gunma prefecture in Japan, with 50 patients in an experimental group and 50 patients used as a control.<sup>23</sup> All patients were elderly and suffered from cerebrovascular disease, degenerative orthopedic disease, Parkinson's disease, spinocerebellar degeneration, diabetic neuropathy, spinal cord injury, or disuse syndrome. Seven of the patients in the experimental group suffered from different types of dementia. The patients in this group received 5 g of dried Lion's Mane mushroom per day in their soup for a 6-month period. All patients were evaluated before and after the treatment

## Lion's Mane

period for their Functional Independence Measure (FIM),<sup>24,25</sup> which is a measure of independence in physical capabilities (eating, dressing, walking, etc.) and in perceptual capacities (understanding, communication, memory, etc.).

The results of this preliminary study show that after six months of taking Lion's Mane mushroom, six out of seven dementia patients demonstrated improvements in their perceptual capacities, and all seven had improvements in their overall FIM score (see Figures 3 and 4). A more extensive clinical study is currently underway to further investigate the findings from this small sample.

The focus of research on medicinal mushrooms until now has been primarily on their anticancer and immune-enhancing properties. The preliminary findings from the studies described above on Lion's Mane mushroom suggest that this mushroom may be a potent inducer of brain tissue regeneration. More research on this subject is clearly needed.

### Correspondence:

Ellen S. Shnidman  
Maitake Products, Inc.  
ellen.s@maitake.com

### References

1. Kawagishi, H. et al. Hericenones C, D, and E, stimulators of Nerve Growth Factor synthesis, from the mushroom *Herichium erinaceum*. *Tetrahedron Lett.* 1991; 32, 4361-4564.
2. Kawagishi, H. et al. Chromans, Hericenones F, G, and H from the mushroom *Herichium erinaceum*. *Phytochemistry.* 1993; 32, 175-178.

## Women's Health Intensive Updates in Botanical and Nutritional Research



Led by Tori Hudson, ND

Sunday, May 23, 2004

9:00 am – 5:30 pm \$150

Bastyr University Campus

14500 Juanita Drive NE, Kenmore, WA 98028

For medical professionals and advanced students  
who have taken gynecology

- Become well informed on HRT research and continued implications of the Women's Health Initiative.
- Update your clinical evaluation and management skills.
- Enhance understanding of treatments for challenging problems.
- Learn about new botanical and herbal research in women's health.

Dr. Hudson, AANP Physician of the Year in 1999, has 18 years clinical experience as a faculty member at National College of Naturopathic Medicine. She is recognized for her research in the field of women's health care.

7.5 CEUs available to NDs and AOM practitioners

Register online at [www.bastyr.edu/continuinged](http://www.bastyr.edu/continuinged) or call 425-602-3075.

**BASTYR**  
UNIVERSITY

FOR 25 YEARS AT THE HEART OF NATURAL MEDICINE


# Lion's Mane




3. Furukawa, S. et al. Biological Significance of Nerve Growth Factor and its Syntheses-Promoting Agent. *Chemistry and Biology*. 1991; 29. (In Japanese)
4. Kawagishi, H. *The Basic Chemistry of Mushrooms and Fungus and Biotechnology*, Shishido, K. (editor). 2002; IPC, 212-228. (In Japanese)
5. Kawagishi, H. Mushroom Yearbook 2002, Efficacy of Mushrooms and its Prospectives. *Plants World*. 2002; 227-332. (In Japanese)
6. Kawagishi, H. *Science of Mushrooms*, Suguwara, R. (editor). Asakura Shoten. 1997; 155-180. (In Japanese)
7. Kawagishi, H. et al. *Search for Bioregulating Agents of Edible Mushrooms and Their Performance Analysis*, Arai, S. (editor). Gakkai Shuppan Center, 1995; 37-43. (In Japanese)
8. Kawagishi, H. et al. Nerve Growth Factor Synthesis-Promoting Agents, Approaches for Studying Vital Function Regulating Agents in Food. *Gakkai Shuppan Center*, 1996; 165-181. (In Japanese)
9. Kawagishi, H. Bioregulating Agents Found in Mushrooms. *Food and Development*. 2002; 37: 14-17. (In Japanese)
10. Kawagishi, H. Bioregulating Agents which Mushrooms Produce. *ILSI*. 2002; 70: 3-14. (In Japanese)
11. Kawagishi, H. The Frontier of the Studies on Functionality of Mushrooms. *Science of Food*. 2002; 296: 4-12. (In Japanese)
12. Kawagishi, H. Bioregulating Agents which Mushrooms Produce, *Kinoko-ken Dayori*. 2001; 18: 5-14. (In Japanese)
13. Kawagishi, H. The Secondary Metabolites of Mushrooms that Promote Synthesis of Nerve Growth Factor. *Japan Mycology Journal*. 2001; 42:11-16. (In Japanese)
14. Kawagishi, H. Mushrooms are a Mine of Bioregulatory Agents with Unique Backbones and Functions. *Chemistry and Biology*. 2001; 39: 497-498. (In Japanese)
15. Kawagishi, H. The Present Situation of Chemical Study on Functionality of Food. *New Food Industry*. 2001; 43: 25-35. (In Japanese)
16. Kawagishi, H. "Good-For-Body" Agents that Edible Mushrooms Produce. *Brain-Tech News*. 2000; 81: 1-5. (In Japanese)
17. Kawagishi, H. Mushroom-Derived Cellular Function Regulatory Agents. *Agriculturization Magazine*. 1994; 68:671-677. (In Japanese)
18. Kawagishi, H. et al. The Inducer of the Synthesis of Nerve Growth Factor from Lion's Mane (*Hericeum erinaceum*). *Explore!* 2002; 11(4): 4-51.
19. Lee, E. W. et al. Two novel diterpenoids, erinacines H and I from the mycelia of *Hericeum erinaceum*. *Biosci. Biotechnol. Biochem*. 2000; 64: 2402-2405
20. Kawagishi, H. et al. Erinacine D, a stimulator of NGF-synthesis, from the mycelia of *Hericeum erinaceum*. *Heterocycl. Commun*. 1996; 2: 51-54.
21. Kawagishi, H. et al. Erinacines, E, F, and G, stimulators of nerve growth factor synthesis, from the mycelia of *Hericeum erinaceum*. *Tetrahedron Lett*. 1996; 37: 7399-7402.
22. Kawagishi, H. et al Erinacines A, B, and C, strong stimulators of nerve growth factor synthesis, from the mycelia of *Hericeum erinaceum*. *Tetrahedron Lett*. 1994; 35: 1569-1572
23. Kasahara, K. et al. The Benefits of Lion's Mane for Aged-disabled. *Gunma Medical Supplementary issue*. 2001; 77-81. (In Japanese)
24. Granger, C. V., Hamilton, B. B., Linacre, J. M., Heinemann, A. W. and Wright, B. D.: Performance profiles of the functional independence measure, *Am. J. Phys. Med. Rehabil*. 72(2), 84-89 (1993).
25. Marino, R. J., Huang, M., Knight, P., Herbison, G. J., Ditunno, J. F. and Segal, M.: Assessing selfcare status in quadriplegia: comparison of the quadriplegia index of function (QIF) and the functional independence measure, *Parsplegia* 31, 225-233 (1993).



**Figure 2**  
Activity of NGF Synthesis with Erinacines A-G  
PC: Epinephrine as positive control



**Figure 3**  
The effect of Lion' Mane Treatment on the perception part of the Functional Independence Measure score



**Figure 4**  
The effect of Lion's Mane Treatment on the total Functional Independence Measure score

